Cargando…

Translational Pharmacokinetic/Pharmacodynamic Modeling of Tumor Growth Inhibition Supports Dose‐Range Selection of the Anti–PD‐1 Antibody Pembrolizumab

Pembrolizumab, a humanized monoclonal antibody against programmed death 1 (PD‐1), has a manageable safety profile and robust clinical activity against advanced malignancies. The lowest effective dose for evaluation in further dose‐ranging studies was identified by developing a translational model fr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lindauer, A, Valiathan, CR, Mehta, K, Sriram, V, de Greef, R, Elassaiss‐Schaap, J, de Alwis, DP
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5270293/ https://www.ncbi.nlm.nih.gov/pubmed/27863176 http://dx.doi.org/10.1002/psp4.12130

Ejemplares similares

Using Model‐Based “Learn and Confirm” to Reveal the Pharmacokinetics‐Pharmacodynamics Relationship of Pembrolizumab in the KEYNOTE‐001 Trial
por: Elassaiss‐Schaap, J, et al.
Publicado: (2016)

Population Pharmacokinetic/Pharmacodynamic Modeling of Tumor Size Dynamics in Pembrolizumab‐Treated Advanced Melanoma
por: Chatterjee, MS, et al.
Publicado: (2016)

Model‐Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti–PD‐1 Monoclonal Antibody in Advanced Solid Tumors
por: Ahamadi, M, et al.
Publicado: (2016)

Pembrolizumab: Role of Modeling and Simulation in Bringing a Novel Immunotherapy to Patients With Melanoma
por: de Greef, R, et al.
Publicado: (2016)

Evaluation of dosing strategy for pembrolizumab for oncology indications
por: Freshwater, Tomoko, et al.
Publicado: (2017)

Pharmacodynamic Parameters of Pharmacokinetic/Pharmacodynamic (PK/PD) Integration Models
por: Zhang, Longfei, et al.
Publicado: (2022)

Translational Pharmacokinetic‐Pharmacodynamic Modeling and Simulation: Optimizing 5‐Fluorouracil Dosing in Children With Pediatric Ependymoma
por: Daryani, VM, et al.
Publicado: (2016)

Evaluation of Natalizumab Pharmacokinetics and Pharmacodynamics: Toward Individualized Doses
por: Serra López-Matencio, Jose M., et al.
Publicado: (2021)

Pharmacokinetic and Pharmacodynamic Considerations in Antimalarial Dose Optimization
por: White, Nicholas J.
Publicado: (2013)

Emerging Insights for Translational Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Studies: Towards Prediction of Nose-to-Brain Transport in Humans
por: Ruigrok, Mitchel J. R., et al.
Publicado: (2015)

Dissecting the Pharmacodynamics and Pharmacokinetics of MSCs to Overcome Limitations in Their Clinical Translation
por: Salvadori, Michela, et al.
Publicado: (2019)

1392. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Inhaled ME1100 Dose Selection
por: Bhavnani, Sujata M, et al.
Publicado: (2018)

Editorial: Pharmacokinetics, pharmacodynamics (PK/PD) of antibiotics: A reality check
por: Zeitlinger, Markus, et al.
Publicado: (2023)

Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing
por: Verheijen, Remy B., et al.
Publicado: (2017)

Cancer Immunotherapy Dosing: A Pharmacokinetic/Pharmacodynamic Perspective
por: Le Louedec, Félicien, et al.
Publicado: (2020)

Pharmacokinetics and pharmacodynamics of repeat dosing of gabapentin in adult horses
por: Gold, Jenifer R., et al.
Publicado: (2022)

The pharmacokinetics and pharmacodynamics of esomeprazole in sheep after intravenous dosing
por: Smith, Joe S., et al.
Publicado: (2023)

Target modulation and pharmacokinetics/pharmacodynamics translation of the BTK inhibitor poseltinib for model-informed phase II dose selection
por: Byun, Joo-Yun, et al.
Publicado: (2021)

Immunogenicity of pembrolizumab in patients with advanced tumors
por: van Vugt, Marianne J. H., et al.
Publicado: (2019)

1390. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Rezafungin (RZF) Dose Selection in Treatment of Candida
por: Lakota, Elizabeth A, et al.
Publicado: (2018)

Variability in the Log Domain and Limitations to Its Approximation by the Normal Distribution
por: Elassaiss‐Schaap, Jeroen, et al.
Publicado: (2020)

Translational Pharmacokinetic/Pharmacodynamic Analysis of MYO‐029 Antibody for Muscular Dystrophy
por: Singh, P, et al.
Publicado: (2016)

Translational Pharmacokinetic/Pharmacodynamic Modeling and Simulation of Oxaliplatin and Irinotecan in Colorectal Cancer
por: Zhu, Jinwei, et al.
Publicado: (2023)

No pharmacodynamic (PD) and pharmacokinetic (PK) interaction of riociguat (BAY 63-2521) and aspirin
por: Frey, Reiner, et al.
Publicado: (2011)

LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baumannii-calcoaceticus Complex (ABC) Infections
por: Bhavnani, Sujata M, et al.
Publicado: (2022)

Effects of Age and Sex on the Single-Dose Pharmacokinetics and Pharmacodynamics of Apixaban
por: Frost, Charles E., et al.
Publicado: (2015)

Evaluation of Amikacin Pharmacokinetics and Pharmacodynamics for Optimal Initial Dosing Regimen
por: Kato, Hideo, et al.
Publicado: (2017)

Pharmacokinetics and Pharmacodynamics of High-Dose Piperacillin–Tazobactam in Obese Patients
por: Veillette, John J., et al.
Publicado: (2021)

Translational Pharmacokinetic–Pharmacodynamic Modeling of NaV1.7 Inhibitor MK-2075 to Inform Human Efficacious Dose
por: Ballard, Jeanine E., et al.
Publicado: (2021)

Pharmacokinetics and Pharmacodynamics of Posaconazole
por: Chen, Lu, et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of Ibrexafungerp
por: McCarthy, Matthew William
Publicado: (2021)

Pharmacokinetics and Pharmacodynamics of Tedizolid
por: Iqbal, Khalid, et al.
Publicado: (2022)

1321. Population Pharmacokinetic (PK) and Pharmacokinetic/Pharmacodynamic (PK/PD) Target Attainment Analyses for Dalbavancin in Pediatric Patients
por: Carrothers, Timothy J, et al.
Publicado: (2020)

In vitro dynamic pharmacokinetic/pharmacodynamic(PK/PD) modeling and PK/PD cutoff of cefquinome against Haemophilus parasuis
por: Xiao, Xia, et al.
Publicado: (2015)

Pharmacokinetic and Pharmacodynamic Evaluation of Marbofloxacin and PK/PD Modeling against Escherichia coli in Pigs
por: Lei, Zhixin, et al.
Publicado: (2017)

Pharmacokinetics and Pharmacodynamics (PK/PD) of Corallopyronin A against Methicillin-Resistant Staphylococcus aureus
por: Rox, Katharina, et al.
Publicado: (2022)

Mechanism-Based Pharmacokinetic–Pharmacodynamic Modeling of the Dopamine D(2) Receptor Occupancy of Olanzapine in Rats
por: Johnson, Martin, et al.
Publicado: (2011)

Pharmacokinetic/pharmacodynamic modeling for the determination of a cimicoxib dosing regimen in the dog
por: Jeunesse, Elisabeth C, et al.
Publicado: (2013)

Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies
por: Laille, Eric, et al.
Publicado: (2015)

Pharmacokinetics and pharmacodynamics of a single dose Nilotinib in individuals with Parkinson's disease
por: Pagan, Fernando L., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_qe0iiv49tvj21tg8f9qnnab7e5